Kenvue Inc. is a consumer health company globally.
| Revenue (TTM) | $15.29B |
| Gross Profit (TTM) | $8.96B |
| EBITDA | $3.47B |
| Operating Margin | 21.60% |
| Return on Equity | 15.70% |
| Return on Assets | 7.07% |
| Revenue/Share (TTM) | $7.97 |
| Book Value | $5.53 |
| Price-to-Book | 3.53 |
| Price-to-Sales (TTM) | 2.48 |
| EV/Revenue | 2.951 |
| EV/EBITDA | 14.08 |
| Quarterly Earnings Growth (YoY) | 46.90% |
| Quarterly Revenue Growth (YoY) | 4.50% |
| Shares Outstanding | $1.92B |
| Float | $1.92B |
| % Insiders | 0.05% |
| % Institutions | 94.92% |
Volatility is currently contracting
Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility.
KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced.
KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a cent.
Black Monday was on Monday, October 19, 1987, almost 40 years ago, and market veterans and long-time investors usually mention one important item: nobody really saw it coming or expected it.
The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's Tylenol with the nonsteroidal anti-inflammatory drug naproxen for up to 12 hours of pain relief.
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2026 financial results before the market opens on August 6, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a cen.
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.
Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
EL, HELE, NUS, KVUE and IPAR stand out as beauty and cosmetics stocks backed by growth strategies for 2H 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KVUE and any ticker you trade — then tracks every position and per-strategy win rate.
